Inquiry Basket
CAS No.: 1595275-60-7
Cat No.: BADC-01669
4.5 
VA-PAB-PBD features a valine-alanine protease-sensitive linker paired with a pyrrolobenzodiazepine (PBD) cytotoxin, offering high potency and selective release for antibody-drug conjugates in oncology applications. Keywords: protease-cleavable linker, PBD toxin, ADC cytotoxin, targeted cancer therapy.
Structure of 1595275-60-7
* For research and manufacturing use only. We do not sell to patients.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
VA-PAB-PBD is a highly potent ADC Cytotoxin with Linker, consisting of the PBD (pyrrolobenzodiazepine) payload attached via a cleavable VA-PAB ADC Linker. This design ensures the ADC payload remains stable during circulation and is released specifically inside antigen-positive target cells. As a defined ADC Cytotoxin, VA-PAB-PBD delivers the PBD payload to tumor cells, enabling DNA minor-groove binding and crosslinking, which inhibits cell proliferation and triggers apoptosis.
The mechanism of VA-PAB-PBD relies on antibody-mediated internalization into cells expressing the target antigen. Once internalized, the VA-PAB linker undergoes proteolytic cleavage within lysosomes, releasing the PBD payload. This precise release ensures that the ADC payload exerts its DNA crosslinking activity selectively, minimizing off-target effects while maintaining potent cytotoxicity in tumor cells. The defined ADC Linker-Payload combination ensures reproducibility and controlled mechanism of action.
VA-PAB-PBD features a cleavable ADC Linker that provides high stability during systemic circulation while enabling predictable intracellular release. The chemical structure allows conjugation to monoclonal antibodies at defined sites, producing homogeneous ADC Cytotoxins with Linker suitable for consistent cytotoxic activity. Its solubility and linker stability support reliable ADC assembly and performance, providing precise payload delivery in antigen-expressing cells.
Applications of VA-PAB-PBD are centered on its function as a defined ADC payload-linker combination for constructing homogeneous antibody-drug conjugates. The protease-sensitive linker ensures controlled intracellular PBD release, supporting consistent DNA crosslinking activity. VA-PAB-PBD is thus an essential reagent for generating ADC Cytotoxins with predictable mechanism, reliable performance, and potent cytotoxic effects in targeted cancer therapy research.
| Catalog | Product Name | CAS | Inquiry |
|---|---|---|---|
| BADC-00340 | PBD dimer | 1222490-34-7 | |
| BADC-00015 | MC-Val-Ala-PBD | 1342820-51-2 | |
| BADC-00738 | MA-PEG4-VA-PBD | 1342820-68-1 | |
| BADC-00670 | Mal-PEG4-VA-PBD | 2259318-50-6 | |
| BADC-00826 | Aniline-MPB-amino-C3-PBD | 2412923-79-4 | |
| BADC-00827 | Py-MPB-amino-C3-PBD | 2412924-07-1 | |
| BADC-01377 | Pyrrolobenzodiazepine (PBD) | 945490-09-5 | |
| BADC-00755 | DBCO-PEG4-VA-PBD |
What is VA-PAB-PBD?
VA-PAB-PBD is a small-molecule cytotoxic payload designed for use in antibody-drug conjugates (ADCs). It combines a pyrrolobenzodiazepine (PBD) dimer with a valine-alanine (VA) dipeptide linker and a para-aminobenzyl (PAB) self-immolative spacer, enabling efficient release upon enzymatic cleavage in target cells.
20/9/2018
Could you kindly advise how VA-PAB-PBD releases the cytotoxic payload?
VA-PAB-PBD releases its PBD dimer payload via proteolytic cleavage of the valine-alanine dipeptide linker by lysosomal enzymes, followed by spontaneous self-immolation of the PAB spacer, ensuring controlled intracellular delivery and cytotoxic activity in targeted cells.
12/5/2019
We are interested in which types of ADCs can use VA-PAB-PBD.
VA-PAB-PBD is suitable for conjugation to monoclonal antibodies targeting solid tumors or hematologic malignancies. Its high potency allows for incorporation into ADCs with various antibody isotypes while maintaining stability in systemic circulation.
13/5/2018
May I ask what the stability profile of VA-PAB-PBD in plasma is?
VA-PAB-PBD exhibits high plasma stability due to the PAB linker and VA dipeptide structure, which resist premature cleavage. This ensures that the payload remains inactive until internalized by target cells, minimizing off-target toxicity.
10/8/2017
Good afternoon! What are the primary research applications of VA-PAB-PBD?
VA-PAB-PBD is primarily used in preclinical ADC development to evaluate cytotoxic efficacy, pharmacokinetics, and targeted delivery in oncology studies. It serves as a model payload for optimizing linker-payload design in ADC research.
9/6/2016
— Dr. Sofia Müller, Senior Chemist (Germany)
VA-PAB-PBD linker showed excellent performance in cytotoxic ADC preparation, with high stability and solubility.
13/5/2018
— Mr. Daniel Peterson, Bioconjugation Specialist (USA)
Consistent batch quality of VA-PAB-PBD allowed smooth scale-up and reproducible ADC conjugation.
9/6/2016
— Dr. Clara Dupuis, ADC Research Scientist (France)
VA-PAB-PBD’s reactivity profile matched our expectations. Minimal side reactions and high conjugation yield.
10/8/2017
— Prof. James Clarke, Medicinal Chemistry (UK)
Reliable VA-PAB-PBD with excellent documentation enabled our team to accelerate preclinical ADC studies.
20/9/2018
— Dr. Helena Fischer, Senior Research Scientist (Germany)
High-purity VA-PAB-PBD simplified our linker-payload conjugation, reducing troubleshooting time.
— Mr. Michael Davis, Chemist (USA)
VA-PAB-PBD is a robust linker with excellent handling properties, supporting reproducible ADC synthesis.
12/5/2019
VA-PAB-PBD
Required fields are marked with *
VA-PAB-PBD
Required fields are marked with *
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.
